Menu

For Healthcare Professionals

Recruitment is underway for a clinical study for patients diagnosed with primary sclerosing cholangitis (PSC) and suffering from itch.

Refer a Patient

About the Study

If you have patients that meet the following criteria, they may be eligible for the VISTAS clinical study:

KEY INCLUSIONS

    • Confirmed PSC diagnosis consistent with the guidelines for the diagnosis and management of PSC published by the AASLD:
      • Large Duct PSC – diagnosis confirmed by prior abnormal cholangiography in the absence of alternative etiologies
      • Small Duct PSC – diagnosis confirmed by prior consistent liver biochemistry changes and consistent liver histology, as well as evidence of an established diagnosis of concomitant IBD
    • Has cholestatic itch caused by PSC
    • 16 years of age or older

KEY EXCLUSIONS

  • Not pregnant or breastfeeding
  • Pruritus associated with an etiology other than PSC
  • Evidence or clinical suspicion of decompensated cirrhosis, or a history of decompensation events
  • History of ileostomy or small bowel surgery/resection or other surgeries that may have disrupted the enterohepatic circulation
  • Evidence, history, or suspicion of other liver diseases
  • History of liver transplantation

What is Primary Sclerosing Cholangitis?

PSC is a rare liver disease that causes damage to the bile ducts outside and sometimes inside the liver. It is frequently associated with inflammatory bowel disease (IBD). While PSC affects mostly men, women can also develop this condition. A common complication from PSC is itching which can lead to fatigue, social isolation, and an overall lower quality of life. Currently there are no approved or effective medications to treat PSC or PSC-associated itch, and some patients ultimately require liver transplantation. Sometimes the itch itself can be an indication for liver transplantation.

About Mirum Pharmaceuticals

Mirum is committed to putting the needs of patients first. We’re transforming lives devastated by rare liver disease through the development and delivery of therapies that address the urgent unmet need and fill a therapeutic void. Through continued clinical evaluation of our investigational therapies, we’re fulfilling our promise to the community.

Left untreated, these diseases can lead to liver failure, liver transplant, and a host of life-altering symptoms that can profoundly impact the quality of life for patients and their families. Some patients may need a liver transplant and are at high risk for many other serious health issues.

For more information about Mirum Pharmaceuticals, visit us at www.mirumpharma.com.

Learn More about the VISTAS Clinical Study
(Healthcare Professionals Only)

If you are interested in learning more about the VISTAS clinical study, including how your patient(s) may participate, please call 1-877-380-3967 to leave a message or fill out the form below to have a qualified nurse get in contact with you:

How did you hear about the VISTAS Clinical Trial? (Check all that apply):

Clinicaltrials.gov

Internet banner ads

Internet search engines (e.g., google, etc.)

Social Media

Word of mouth

Do not remember

This is a required question. Please answer and resubmit.

[Healthcare professionals only] Please provide your contact information so one of our qualified healthcare professionals can contact you regarding the VISTAS clinical study.

This is a required question. Please answer and resubmit.
This is a required question. Please answer and resubmit.
This is a required question. Please answer and resubmit.
This is a required question. Please answer and resubmit.
This is a required question. Please answer and resubmit.
This is a required question. Please answer and resubmit.
This is a required question. Please answer and resubmit.
This is a required question. Please answer and resubmit.
This is a required question. Please answer and resubmit.
This is a required question. Please answer and resubmit.
This is a required question. Please answer and resubmit.
This is a required question. Please answer and resubmit.
This is a required question. Please answer and resubmit.

Submit Your Patient’s Contact Information (Optional)
Thank you for completing the questionnaire.

Please provide contact information for only adult patients 18 years or older.

A nurse from the study team will contact your adult patient to review eligibility and provide information about the study.

By checking the box below, I understand that the personal information I have provided may be collected, shared, used and/or transferred to the clinical study team and their representatives for the sole purpose of enabling me (the HCP), and/or the patient I have entered above to be contacted regarding a clinical trial.

By checking this box, I verify that:

This is a required question. Please answer and resubmit.
  • The name and phone number I have provided belong to my patient, are correct, and I attest that the contact person is interested in being contacted regarding a clinical trial (in order to help prevent unauthorized use of this service).
  • I confirm that I have read and understood the Privacy Policy.
  • The contact person is 18 years or older.
  • My patient has agreed to be contacted via phone about clinical study options for Primary Sclerosing Cholangitis (PSC).
Share with a Patient
Clicking the above button will copy a short description and link to the VISTAS clinical study website to your clipboard, which can then be pasted into and edited in any secure messaging platform you use to communicate to patients. Copied!

Share This Opportunity